P53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 7, 2013, Pages 1207-1210

  Häfner, Norman ^a   Nicolaus, Kristin ^a   Weiss, Stefanie ^a   Frey, Manfred ^b   Diebolder, Herbert ^a   Rengsberger, Matthias ^a   Dürst, Matthias ^a   Runnebaum, Ingo B ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Steinbeis Transferzentrum Angewandte Biologische Chemie   (Germany)

Author keywords

Biomarker; Epithelial ovarian cancer; p53 autoantibody

Indexed keywords

AUTOANTIBODY; CA 125 ANTIGEN; P53 AUTOANTIBODY; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MEDICAL RECORD; MINIMAL RESIDUAL DISEASE; MONITORING; OVARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AUTOANTIBODIES; CA-125 ANTIGEN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM, RESIDUAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879242090     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1432-2     Document Type: Article

References (20)

1. Anderson KS, LaBaer J (2005) The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4(4):1123-1133 (Pubitemid 41208670)
2. Bauerschlag DO, Schem C, Weigel MT et al (2010) The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer. J Cancer Res Clin Oncol 136(1):79-88
3. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473-2483
4. Cramer DW, Bast RC Jr, Berg CD et al (2011) Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 4(3):365-374
5. Gadducci A, Ferdeghini M, Buttitta F et al (1998) Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. Anticancer Res 18(5B):3763-3765 (Pubitemid 28564261)
6. Gumus E, Erdamar S, Demirel G et al (2004) Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 11(12):1070-1077 (Pubitemid 40053006)
7. Hori SS, Gambhir SS (2011) Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med 3(109):109ra116
8. Lu D, Kuhn E, Bristow RE et al (2011) Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 122(3):560-566
9. Lu H, Ladd J, Feng Z et al (2012) Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) 5(8):1036-1043
10. Mastropaolo W, Fernandez Z, Miller EL (1986) Pronounced increases in the concentration of an ovarian tumor marker, CA-125, in serum of a healthy subject during menstruation. Clin Chem 32(11):2110-2111 (Pubitemid 17029214)
11. Mongia SK, Rawlins ML, Owen WE et al (2006) Performance characteristics of seven automated CA 125 assays. Am J Clin Pathol 125(6):921-927 (Pubitemid 43801543)
12. Pedersen JW, Gentry-Maharaj A, Fourkala EO et al. (2012) Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br J Cancer doi: 10.1038/bjc.2012.517
13. Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484-2496
14. Riedinger JM, Wafflart J, Ricolleau G et al (2006) CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol 17(8):1234-1238 (Pubitemid 44288214)
15. Rohayem J, Conrad K, Zimmermann T et al (1999) Comparison of the diagnostic accuracy of three commercially available enzyme immunoassays for anti-p53 antibodies. Clin Chem 45(11):2014-2016 (Pubitemid 29522014)
16. Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60(7):1777-1788 (Pubitemid 30207629)
17. Takeda A, Shimada H, Nakajima K et al (2001) Monitoring of p53 autoantibodies after resection of colorectal cancer: relationship to operative curability. Eur J Surg 167(1):50-53 (Pubitemid 32066221)
18. Tan HT, Low J, Lim SG et al (2009) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276(23):6880-6904
19. Vogl FD, Frey M, Kreienberg R et al (2000) Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 83(10):1338-1343
20. Zalcman G, Schlichtholz B, Tredaniel J et al (1998) Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clin Cancer Res 4(6):1359-1366 (Pubitemid 28265217)